

**Figure 1** Patient's *SI* genetic profiling and in vitro characterisation of the enzymatic activity of corresponding DNA variants. (A) The patient's DNA was sequenced via clinical exome sequencing (Illumina) service at the Australian Genomic Research Facility ([www.agrf.org.au](http://www.agrf.org.au)), and confirmed via ad hoc resequencing of the *SI* gene (Illumina targeted assay) at IKMB in Kiel Germany; (B/C) COS-1 cells were transfected or cotransfected with cDNAs encoding *SI* variants of interest (wt, [H1684Q, G1760V] and [V15F]), and cell surface expression (B) and sucrase activity (C) determined relative to wt (set as reference 100%), upon immunoprecipitation and quantification/normalisation with appropriate antibodies as previously described.<sup>3</sup> \*Student t-test  $p < 0.05$ . *SI*, sucrase-isomaltase.

## Adult sucrase-isomaltase deficiency masquerading as IBS

Recently in *Gut*, several publications reported an increased prevalence of hypomorphic (defective) sucrase-isomaltase (*SI*) gene variants in patients with irritable bowel syndrome (IBS),<sup>1,2</sup> and the association with impaired cell-surface expression and reduced digestive function of the corresponding enzyme.<sup>3</sup> In addition, hypomorphic *SI* carriers have shown reduced response compared with non-carriers in a low-FODMAP (fermentable oligo- di- mono-saccharides and polyols) trial of IBS patients with diarrhoea.<sup>4</sup> These and other studies,<sup>5,6</sup> including recent large population-based surveys,<sup>7</sup> raise the question whether genetic defects in the *SI* gene may be sought to explain abdominal symptoms in some patients with IBS.

A 23-year-old patient was referred with a diagnosis of IBS due to his long-standing postprandial diarrhoea associated with bloating, abdominal pain and nausea. He also had marked fatigue, headaches and mouth ulcers. He had symptoms since infancy without signs of malnutrition or failure-to-thrive. Extensive investigations

excluded alternate causes of diarrhoea, including coeliac and inflammatory bowel disease, pancreatic exocrine insufficiency and bile acid diarrhoea. A low FODMAP diet worsened symptoms and psychological interventions were not helpful.

We hypothesised the involvement of *SI* defects. Resequencing of the gene identified three coding variants of interest (H1684Q, G1760V and V15F), which were assigned to a heterozygous compound combination as [H1684Q, G1760V] + [V15F] (figure 1A) based on sequencing data from additional family members (not shown). While [V15F] is known to have 35% reduced disaccharidase activity, an in vitro system was developed in order to study the [H1684Q, G1760V] variant by testing its disaccharidase activity in transfected COS cells, as previously described.<sup>13</sup> This variant showed no expression at the cell surface (figure 1B), corresponding to only residual disaccharidase activity (25%) when coexpressed with [V15F], also defective, mimicking the patient's heterozygous state (figure 1C).

Follow-up clinical investigations of *SI* function showed marked impairment of sucrase and maltase activities in duodenal biopsies and, on breath hydrogen tests, a sustained hydrogen response to sucrose, which was abrogated in the presence of sacrosidase (figure 2). Formal dietary reduction of starches and sucrose was associated with a 50% symptom response, and a therapeutic trial of sacrosidase (Sucraid, QOL Medical, FL) led to complete resolution of symptoms (figure 2). Withholding then reinstating sacrosidase verified response to it.


These results indicate that our patient has congenital *SI* deficiency (CSID), considered a rare autosomal recessive condition

most commonly identified in infants with symptoms of diarrhoea, malabsorption and failure-to-thrive. While a few CSID cases have also been described in adults,<sup>8</sup> there is accumulating evidence that partial

### A *SI* phenotype *ex vivo*

Enzyme	Duodenal activity (U/g)	Reference (U/g)
Lactase	43	>20
Sucrase	7	>50
Maltase	36	>140

### B *SI* phenotype *in vivo*



### C Therapeutic trial

Therapy	Response in symptoms
Dietary restriction of starch and sucrose	50% reduction
Sacrosidase	Resolution

**Figure 2** Characterisation of *SI* deficiency in the studied patient. (A) Enzymatic activity *ex vivo* in duodenal biopsies; (B) Sucrase breath hydrogen testing with and without sacrosidase; (C) Therapeutic trials with sucrose-reducing and starch-reducing diet, and sacrosidase. *SI*, sucrase-isomaltase.

SI deficiency (possibly as in hypomorphic carriers) is associated with increased risk of IBS in the general population. Hence, a clinical continuum across sucrose and starch malabsorption may be envisaged, which spans a spectrum of functionally diverse DNA variations in the *SI* gene. These include homozygous and heterozygous combinations of variously defective *SI* variants, resulting in a genotype-mediated gradient of disease risk ranging from mild(er) IBS to severe CSID.

Thus, in a small fraction of patients with IBS, symptoms might be wholly or partly due to SI dysfunction associated with hypomorphic variants of the *SI* gene. Symptoms that raise the possibility of a defective *SI* gene may include onset in childhood, predominantly postprandial timing and a poor response to FODMAP restriction, which does not reduce sucrose and only partially reduces starch content. If a role for SI deficiency is suspected, it should be pursued and, while the clinical interpretation of tissue hydrolase activities and hydrogen breath tests requires further elucidation (especially in milder *SI* defects), *SI* genotyping and/or sequencing represents a valuable contribution to clinical profiling. Such findings can lead to gratifying amelioration of symptoms, although specific enzyme therapy is currently limited by cost and availability.

Anna Foley,<sup>1</sup> Emma Phoebe Halmos,<sup>1</sup> Diab M Husein,<sup>2</sup> Sasha Rachel Fehily,<sup>1</sup> Britt-Sabina Löscher,<sup>3</sup> Andre Franke,<sup>3</sup> Hassan Y Naim,<sup>2</sup> Peter R Gibson,<sup>1</sup> Mauro D'Amato<sup>4,5,6</sup>

<sup>1</sup>Department of Gastroenterology, Alfred Health and Monash University, Melbourne, Victoria, Australia

<sup>2</sup>Department of Biochemistry, University of Veterinary Medicine Hannover, Hannover, Germany

<sup>3</sup>Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany

<sup>4</sup>Gastrointestinal Genetics Lab, CIC bioGUNE - BRTA, Derio, Spain

<sup>5</sup>School of Biological Sciences, Monash University, Melbourne, Victoria, Australia

<sup>6</sup>Ikerbasque, Basque Foundation for Science, Bilbao, Spain

**Correspondence to** Professor Mauro D'Amato, Gastrointestinal Genetics Lab, CIC bioGUNE - BRTA, Derio, Bizkaia, Spain; mdamato@cicbiogune.es and Professor Peter R Gibson, Department of Gastroenterology, Central Clinical School, Alfred Hospital, Melbourne, VIC, Australia; peter.gibson@monash.edu

**Correction notice** This article has been corrected since it published Online First. The author's name, Hassan Y Naim, has been updated.

**Twitter** Mauro D'Amato @damato\_mauro

**Contributors** Afo, EPH, SRF and PRG patient characterisation; DMH and HN in vitro experimentation and disaccharidase assays; B-SL, AFR and MD'A genome sequence analysis and interpretation; MD'A and PRG: study conception and supervision, project planning, data interpretation, manuscript drafting; Afo, EPH,

DMH, SRF, B-SL, AFR, MD'A and PRG critical revision of the manuscript.

**Funding** The study was supported by grants from the Spanish Ministry of Science and Innovation (MICINN PID2020-113625RB) to MD'A, the German Research Foundation (DFG 331/13-1) to HN, and QOL Medical to MD'A and HN.

**Competing interests** MD'A and HN have received financial support from QOL Medical, in the form of unrestricted research grants; PRG, EPH: Monash University financially benefits from the sales of a digital application, booklets and online courses on the FODMAP diet; PRG has published two educational/recipe books on diet; other authors have nothing to declare.

**Patient consent for publication** Obtained.

**Ethics approval** Case report, formal ethics approval not needed in accordance with local ethics department guidelines.

**Provenance and peer review** Not commissioned; internally peer reviewed.



## OPEN ACCESS

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PRG and MD are joint senior authors.



**To cite** Foley A, Halmos EP, Husein DM, *et al.* *Gut* 2022;**71**:1237–1238.

Received 17 September 2021

Accepted 29 September 2021

Published Online First 6 October 2021

*Gut* 2022;**71**:1237–1238. doi:10.1136/gutjnl-2021-326153

### ORCID iDs

Britt-Sabina Löscher <http://orcid.org/0000-0001-9022-9017>

Hassan Y Naim <http://orcid.org/0000-0003-4884-8425>

Peter R Gibson <http://orcid.org/0000-0001-9108-1712>

Mauro D'Amato <http://orcid.org/0000-0003-2743-5197>

### REFERENCES

- Henström M, Diekmann L, Bonfiglio F, *et al.* Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. *Gut* 2018;**67**:263–70.
- Thingholm L, Rühlemann M, Wang J, *et al.* Sucrase-isomaltase 15Phe IBS risk variant in relation to dietary carbohydrates and faecal microbiota composition. *Gut* 2019;**68**:177–8.
- Husein DM, Naim HY. Impaired cell surface expression and digestive function of sucrase-isomaltase gene variants are associated with reduced efficacy of

low FODMAPs diet in patients with IBS-D. *Gut* 2020;**69**:1538–9.

- Zheng T, Eswaran S, Phothenhauer AL. Reduced efficacy of fodmap diet in IBS-D patients carrying hypomorphic sucrase-isomaltase (*SI*) variants. *Gut* 2020;**69**:397–8.
- García-Etxebarria K, Zheng T, Bonfiglio F. Increased prevalence of rare sucrase-isomaltase (*SI*) pathogenic variants in IBS patients. *Clin Gastroenterol Hepatol* 2018;**16**:1673–6.
- Chumpitazi BP, Lewis J, Cooper D, *et al.* Hypomorphic *SI* genetic variants are associated with childhood chronic loose stools. *PLoS One* 2020;**15**:e0231891.
- Zheng T, Camargo-Tavares L, Bonfiglio F, *et al.* Rare hypomorphic sucrase isomaltase variants in relation to irritable bowel syndrome risk in UK Biobank. *Gastroenterology* 2021;**4**. doi:10.1053/j.gastro.2021.06.063. [Epub ahead of print: 26 Jun 2021].
- Chiruvella V, Cheema A, Arshad HMS, Sharjeel Arshad HM, *et al.* Sucrase-isomaltase deficiency causing persistent bloating and diarrhea in an adult female. *Cureus* 2021;**13**:e14349.